Interferon therapy in myelomatosis.

No abstract is available for this paper.

• Publication year

  1979

• Venue

  The Lancet

• Publication date

  1979-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(79)90770-0PMID 84901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor effects of interferon.

  1978cited by this paper
• Interferons: Anti-neoplastic drugs?

  1977cited by this paper
• Diagnosis and Treatment of Multiple Myeloma

  1970cited by this paper
• Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

  1966cited by this paper

• Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses

  2023cites this paper
• Genomic and transcriptional profiling stratifies VQ myeloma lines into two clusters with distinct risk signatures and drug responses

  2022cites this paper
• Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives

  2022cites this paper
• Facts and Hopes in Multiple Myeloma Immunotherapy

  2021cites this paper
• Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity

  2020cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice

  2019cites this paper
• Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals

  2019cites this paper
• IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD 38

  2018cites this paper
• IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.

  2018cites this paper
• Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains

  2018cites this paper
• Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

  2018cites this paper
• Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

  2017cites this paper
• Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity

  2016cites this paper
• Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.

  2016cites this paper
• Monoclonal gammopathy of undetermined significance : natural course and comorbidities

  2016cites this paper
• Type I interferons in anticancer immunity

  2015cites this paper
• A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib

  2014cites this paper
• Current Status of Maintenance Therapy in Multiple Myeloma

  2014cites this paper
• The evolving field of post-transplant therapy in multiple myeloma

  2014cites this paper
• New developments in post-transplant maintenance treatment of multiple myeloma.

  2013cites this paper
• Part II: role of maintenance therapy in transplant-ineligible patients.

  2013cites this paper
• Evolving therapeutic paradigms for multiple myeloma: back to the future

  2013cites this paper
• Role of consolidation/maintenance therapy in multiple myeloma.

  2013cites this paper
• IMWG consensus on maintenance therapy in multiple myeloma.

  2012cites this paper
• A New Ally for Interferon-alpha in Cancer Therapy

  2012cites this paper
• Interferons and Interferon Inducers: Development of Clinical Usefulness and Therapeutic Promise

  2012cites this paper
• A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

  2011cites this paper
• Chemotherapy of Viral Infections

  2011cites this paper
• Interferon-alpha in the treatment of multiple myeloma.

  2011cites this paper
• Interferon alpha2 in the treatment of hematological malignancies. Status and perspectives.

  2011cites this paper
• stimulated gene factor 3 defective in the activation of the DNA-binding factor interferon- Primary leukemia cells resistant to alpha-interferon in vitro are

  2011cites this paper
• Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

  2010cites this paper
• Effects of native human leukocyte interferon-alpha and recombinant human interferon-alpha on P3-X63-Ag8.653 mouse myeloma cell growth.

  2009cites this paper
• 2 translocations, t(11;14) and t(1;6), in a patient with plasma cell leukaemia and 2 populations of plasma cells.

  2009cites this paper
• Population-based studies on familiality and prognosis in patients with monoclonal gammopathies

  2009cites this paper
• Interferons: therapy for cancer

  2009cites this paper
• Effects of Native Human Leukocyte Interferon-α and Recombinant Human Interferon-α on P3-X63-Ag8.653 Mouse Myeloma Cell Growth

  2009cites this paper
• The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system.

  2009cites this paper
• Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

  2009cites this paper
• Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden.

  2009cites this paper
• Immune reactions and long-term therapy with human leukocyte interferon.

  2009cites this paper
• Interferons and osteosarcoma.

  2007cites this paper
• An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b.

  2007cites this paper
• Maintenance therapy in multiple myeloma

  2007cites this paper
• Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

  2007cites this paper
• Interferons: the pathways of discovery. II. Immunomodulatory, in vivo and applied aspects.

  2007cites this paper
• Prolonged survival in resistant myeloma after treatment with interferon—a case report and review

  2006cites this paper
• Surface Antigens Proliferation of Hairy Cells Coincides with Modulation of Cell-Interferon-inhibited α B-Cell Growth Factor-induced and Updated Version

  2006cites this paper
• Bence-Jones Myeloma with Pleural Effusion: Response to <*-Interferon and Combined Chemotherapy

  2006cites this paper
• Phase I Study of a2-Interferon plus Doxorubicin in Patients with Solid Tumors1

  2006cites this paper
• Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?

  2006cites this paper
• Biological and Clinical Properties of the Type 1 Interferons

  2006cites this paper
• Interferon therapy: Pharmacokinetic and pharmacological aspects

  2005cites this paper
• The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme

  2005cites this paper
• Interferon production and virus replication in lymphoblastoid cells infected with different viruses

  2005cites this paper
• Multiple myeloma: biology and therapy

  2005cites this paper
• Clinical effect of interferon in malignant brain tumours

  2005cites this paper
• Treatment of Multiple Myeloma With Recombinant a-Interferon

  2005cites this paper
• Low-dose interferon-alpha in stage-I multiple myeloma and in IgM monoclonal gammopathy

  2005cites this paper
• Management of multiple myeloma

  2005cites this paper
• Clinical and immunological studies of human fibroblast interferon

  2004cites this paper
• Activity of human leukocyte interferon in a human tumor cloning system

  2004cites this paper
• The antitumor effects of human lymphoblastoid interferon on human renal cell carcinoma in athymic nude mice

  2004cites this paper
• The treatment of cancer patients with human lymphoblastoid interferon

  2004cites this paper
• Multiple myeloma

  2004cites this paper
• A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer

  2004cites this paper
• Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects

  2004cites this paper
• Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy

  2004cites this paper
• Interferons: Current status and future directions of this prototypic biological

  2004cites this paper
• A phase I trial of recombinant gamma interferon in patients with cancer

  2004cites this paper
• Effectiveness of propagermanium treatment in multiple myeloma patients

  2004cites this paper
• Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-interferon and cimetidine

  2004cites this paper
• Remission Maintenance in Multiple Myeloma

  2004cites this paper
• A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion

  2004cites this paper
• Anti‐tumour activity of interferon‐alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation

  2003cites this paper
• Effects of Interferon-α on Cell Cycle Regulatory Proteins in Leukemic Cells

  2003cites this paper
• Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon‐α with melphalan and prednisone (MP) and interferon‐α (IFN‐α) in patients with good‐prognosis multiple myeloma: a prospective randomized study

  2001cites this paper
• Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma.

  2001cites this paper
• Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.

  2001cites this paper
• Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT)

  2001cites this paper
• Biologic response modifiers in pediatric cancer.

  2001cites this paper
• European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma.

  2001cites this paper
• Progress in haematopoietic stem cell transplantation for multiple myeloma

  2000cites this paper
• Second-generation interferons for cancer: clinical targets.

  2000cites this paper
• Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

  2000cites this paper
• Interferon in Multiple Myeloma - Summary of Treatment Results and Clinical Implications

  2000influential citation
• Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.

  2000cites this paper
• The role of alpha-interferon in multiple myeloma.

  1999cites this paper
• Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade.

  1999cites this paper
• Interferon-α elevates pulmonary blood pressure in sheep—the role of thromboxane cascade

  1999cites this paper
• MRC trial of α2b‐interferon maintenance therapy in first plateau phase of multiple myeloma

  1998cites this paper
• Interferon in the Treatment of Multiple Myeloma.

  1998cites this paper
• Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology)

  1998cites this paper
• Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha

  1998cites this paper
• A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results

  1998cites this paper
• Interferon Alpha and Beta2 Microglobulin in Multiple Myeloma

  1998cites this paper
• Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines.

  1998cites this paper
• Should-alpha-interferon be included as standard treatment in multiple myeloma?

  1998cites this paper
• MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults.

  1998cites this paper